Back to Trials
NCT07627074Recruiting

Weight Loss in Adults Using Semaglutide (Real-world Study)

Novo Nordisk A/S

Start Date

5/12/2026

Completion Date

6/1/2026

Summary

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Initiation of semaglutide for weight management during the study period. * Age more than or equal to (≥) 18 at treatment initiation * Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2. * Other inclusion criteria as defined in the protocol are applicable. Exclusion Criteria: * Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs). * Bariatric surgery at baseline. * Diabetes at baseline. * Pregnancy at baseline.

Interventions

DRUG

Semaglutide

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

OverweightObesity

Locations

Novo Nordisk Investigational Site

Seattle, Washington 98039

United States

Novo Nordisk Investigational Site

London,

United Kingdom